Arip Koyshybaev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arip Koyshybaev has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Saule Balmagambetova
Department of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe 030019, Kazakhstan
3 shared publications - Elnara Ismagulova
ENT Diseases Department, West Kazakhstan Marat Ospanov State Medical University, Maresyev Str. 68, Aktobe 030019, Kazakhstan
2 shared publications - Kanshaiym Sakiyeva
Department of Obstetrics and Gynecology, West Kazakhstan Marat Ospanov Medical University, 030019, 68, Maresyev Street, Aktobe, Kazakhstan
2 shared publications - Olzhas Urazayev
Department of Oncology, West Kazakhstan Marat Ospanov Medical University, 030019, 68, Maresyev Street, Aktobe, Kazakhstan
2 shared publications - Ainel Urazova
Chemotherapy Division at University Medical Center, Building 8G, Zhanakonys, Aktobe 030017, Kazakhstan
1 shared publication - Andrea Tinelli
Department of Obstetrics and Gynecology, CERICSAL (CEntro di RIcerca Clinico SALentino), “Veris delli Ponti Hospital”, Via Giuseppina Delli Ponti, 73020 Scorrano, Italy
1 shared publication
Latest Publications
- Open Access
- 6 November 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (11) , 2714
Early Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol
The prognosis of cancer treatment depends on, among other aspects, the cardiotoxicity of chemotherapy. This research aims to create a feasible algorithm for the early diagnosis of antitumor therapy cardiotoxicity in breast cancer patients. The paper represents a protocol for a prospective cohort study with N 120 eligible participants admitted for treatment with anthracyclines and/or trastuzumab. These patients will be allocated into four risk groups regarding potential cardiotoxic complications. Patients will be examined five times every three months for six biomarkers: cardiac troponin I (cTnI), brain natriuretic peptide (BNP), C-reactive protein (CRP), myeloperoxidase (MPO), galectin-3 (Gal-3), and D-dimer, simultaneously with echocardiographic methods, including speckle tracking. The adjusted relative risk (aOR) of interrupting an entire course of chemotherapy due to cardiotoxic events will be assessed using multiple analyses of proportional Cox risks. The Cox model will also assess associations between baseline biomarker values and time to cardiotoxic events. Moreover, partly conditional survival models will be applied to determine associations between repeated assessments of changes in biomarkers from baseline and time to cancer therapy-related cardiac dysfunction. All models will be adjusted for cancer therapy regimen, baseline LVEF, groups at risk, baseline biomarker values, and age. The decision-tree and principal component analysis (PCA) methods will also be applied. Thus, feasible patterns will be detected.
- 6 November 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (11) , 2714
Open AccessEarly Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol
The prognosis of cancer treatment depends on, among other aspects, the cardiotoxicity of chemotherapy. This research aims to create a feasible algorithm for the early diagnosis of antitumor therapy cardiotoxicity in breast cancer patients. The paper represents a protocol for a prospective cohort study with N 120 eligible participants admitted for treatment with anthracyclines and/or trastuzumab. These patients will be allocated into four risk groups regarding potential cardiotoxic complications. Patients will be examined five times every three months for six biomarkers: cardiac troponin I (cTnI), brain natriuretic peptide (BNP), C-reactive protein (CRP), myeloperoxidase (MPO), galectin-3 (Gal-3), and D-dimer, simultaneously with echocardiographic methods, including speckle tracking. The adjusted relative risk (aOR) of interrupting an entire course of chemotherapy due to cardiotoxic events will be assessed using multiple analyses of proportional Cox risks. The Cox model will also assess associations between baseline biomarker values and time to cardiotoxic events. Moreover, partly conditional survival models will be applied to determine associations between repeated assessments of changes in biomarkers from baseline and time to cancer therapy-related cardiac dysfunction. All models will be adjusted for cancer therapy regimen, baseline LVEF, groups at risk, baseline biomarker values, and age. The decision-tree and principal component analysis (PCA) methods will also be applied. Thus, feasible patterns will be detected.
- Open Access
- 1 November 2020
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 34, 100661
Colposcopy accuracy in diagnosing cervical precancerous lesions in western Kazakhstan
- 1 November 2020
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 34, 100661
Open AccessColposcopy accuracy in diagnosing cervical precancerous lesions in western Kazakhstan
- Open Access
- 2 May 2019
- Published by IntechOpen
Results of a Survey Concerning Cervical Cancer Risk Factors among Women in Western Kazakhstan
During 2014–2017, a survey concerning risk factors for cervical cancer involving 1166 clinically healthy women and 65 having CaCx was conducted in Western Kazakhstan. Only 34.7% of interviewees constantly participated in state-sponsored screening program, while 37.3% ignored screening in free state-sponsored clinics. Favorable attitude toward vaccination stated 22.9% of the respondents, whereas 38.8% knew nothing, and 33.6% could not clarify their position in this issue. Education is a key factor for better perception of preventive measures—69.2% of the respondents with higher education are aware of vaccination (p ≤ 0.00001, Cramer’s V 0.18, χ2–23.1). Social profiles of HPV-infected and CaCx-diseased women differ significantly and, mainly, by standard of living and occupational status. The likelihood of the CaCx onset in Western Kazakhstan decreased by 14 times at relatively high standard of living (OR 0.0713, p = 0.024) and by 3.3 times provided at least irregular participation in screening (OR 0.3384, p = 0.0304). Overall, the findings are quite able to contribute to an understanding why women become affected by CaCx. Low standard of living due to lack of education, low attendance of screening, and low awareness on preventive measures‑all these reasons are interacted and constitute a set of universal triggers for vulnerability toward CaCx.
- 2 May 2019
- Published by IntechOpen
Open AccessResults of a Survey Concerning Cervical Cancer Risk Factors among Women in Western Kazakhstan
During 2014–2017, a survey concerning risk factors for cervical cancer involving 1166 clinically healthy women and 65 having CaCx was conducted in Western Kazakhstan. Only 34.7% of interviewees constantly participated in state-sponsored screening program, while 37.3% ignored screening in free state-sponsored clinics. Favorable attitude toward vaccination stated 22.9% of the respondents, whereas 38.8% knew nothing, and 33.6% could not clarify their position in this issue. Education is a key factor for better perception of preventive measures—69.2% of the respondents with higher education are aware of vaccination (p ≤ 0.00001, Cramer’s V 0.18, χ2–23.1). Social profiles of HPV-infected and CaCx-diseased women differ significantly and, mainly, by standard of living and occupational status. The likelihood of the CaCx onset in Western Kazakhstan decreased by 14 times at relatively high standard of living (OR 0.0713, p = 0.024) and by 3.3 times provided at least irregular participation in screening (OR 0.3384, p = 0.0304). Overall, the findings are quite able to contribute to an understanding why women become affected by CaCx. Low standard of living due to lack of education, low attendance of screening, and low awareness on preventive measures‑all these reasons are interacted and constitute a set of universal triggers for vulnerability toward CaCx.